Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 13Thoracic 5Gynecologic 4Breast 3Head & Neck 2Genitourinary 2Dermatologic 2Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 36Head and Neck Neoplasms 19Oropharyngeal Neoplasms 7Recurrence 6Melanoma 6Prostatic Neoplasms 5Carcinoma, Squamous Cell 5Small Cell Lung Carcinoma 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Mouth Neoplasms 3Esophageal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Stomach Neoplasms 2Sarcoma 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Laryngeal Neoplasms 2Laryngeal Diseases 2Esophageal Squamous Cell Carcinoma 2Turcot syndrome 1

Interventions

pembrolizumab 30Nivolumab 11atezolizumab 8Docetaxel 8Cisplatin 7Carboplatin 7Gemcitabine 6fludarabine 5Trastuzumab 5Paclitaxel 5Ipilimumab 5Fluorouracil 5Cyclophosphamide 5spartalizumab 4cemiplimab 4avelumab 4Polymerase Chain Reaction 4Cetuximab 4Capecitabine 4Bevacizumab 4130-nm albumin-bound paclitaxel 4aldesleukin 3Taxes 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3Leucovorin 3Interleukin-2 3Gene Expression Profiling 3Drug Therapy 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stomach Neoplasms × durvalumab × Head & Neck × Clear all
NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

Phase 2 Active not recruiting
40 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡